Glenmark Life Sciences Ltd Stock Price: Glenmark Life Share Price Today

Glenmark Life Sciences Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

₹1,010

Prev. Close

₹994.6

Turnover(Lac.)

₹698.37

Day's High

₹1,010

Day's Low

₹992

52 Week's High

₹1,335.1

52 Week's Low

₹819.05

Book Value

₹229.8

Face Value

₹2

Mkt Cap (₹ Cr.)

12,278.86

P/E

25.28

EPS

39.6

Divi. Yield

0.5

Glenmark Life Sciences Ltd Corporate Action

8 May 2025

12:00 AM

Board Meeting

Agenda : Audited Result

5 Sep 2024

12:00 AM

AGM

Announcement Date: 05 Sep, 2024

Alivus Life Sciences Ltd NEWS AND UPDATE

Glenmark Set to Enter $421 Million US ADHD Drug Market

17 Apr 2025|03:29 PM

The drug consists of a combination of dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate, and amphetamine sulfate.

Glenmark Life Sciences’ Q2 net profit falls 20% y-o-y

25 Oct 2024|12:27 PM

The Mumbai-based company's income from operations decreased by roughly 15% to ₹507 Crore in the three months ended September 30.

Top stocks for today - 25th October 2024

25 Oct 2024|08:14 AM

Here are some of the stocks that may see significant price movement today: ITC, Kansai Nerolac, Coromandel International, etc.

Glenmark Pharmaceuticals divests stake in Glenmark Life after Nirma Acquisition

11 Jul 2024|01:16 PM

The sale will be conducted through the stock exchange mechanism, adhering to applicable legal requirements.

Y/e 31 Mar( In .Cr)	Mar-2024	Mar-2023	Mar-2022	Mar-2021
Equity Capital	24.51	24.51	24.51	1.96
Preference Capital	0	0	0	0
Reserves	2,307.82	2,113.7	2,029.81	750.79
Net Worth	2,332.33	2,138.21	2,054.32	752.75
Minority Interest

Y/e 31 Mar( In .Cr)	Mar-2021
Revenue	1,885.16
yoy growth (%)
Raw materials	-905.49
As % of sales	48.03
Employee costs	-149.13

Y/e 31 Mar( In .Cr)	Mar-2021
Profit before tax	470.94
Depreciation	-33.39
Tax paid	-119.36
Working capital
Other operating items

Y/e 31 Mar	Mar-2021
Growth matrix (%)
Revenue growth
Op profit growth
EBIT growth
Net profit growth

Particulars (Rupees in Crores.)	Mar-2021	Mar-2020	Mar-2019
Gross Sales	1,885.17	1,537.31	886.42
Excise Duty	0	0	0
Net Sales	1,885.17	1,537.31	886.42
Other Operating Income	0	0	0
Other Income	0.81	11.99	0.44

Company Name	LTP (₹)	P/E (%)	Mkt.Cap (₹Cr.)	NP Qtr (₹Cr.)	Div.Yield (%)	Sales Qtr (₹.Cr)	Book Value (₹)
Sun Pharmaceutical Industries Ltd SUNPHARMA	1,669.8	93.52	4,00,520.99	2,000.46	0.96	7,107.14	101.44
Divis Laboratories Ltd DIVISLAB	6,616	79.48	1,75,574.28	667	0.45	2,536	561.08
Cipla Ltd CIPLA	1,513.8	25.39	1,22,186	1,485.4	1.06	4,254.47	397.41
Dr Reddys Laboratories Ltd DRREDDY	1,321.5	20.61	1,10,263.53	1,200.7	0.61	5,546.3	345.76
Torrent Pharmaceuticals Ltd TORNTPHARM	3,222.5	57.29	1,09,167.44	474	0.99	2,385	224.33

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

View All Peer Comparision

MORE ABOUT Glenmark Life Sciences Ltd

Management

Register Office

Registrar Office

Managing Director & CEO

Yasir Yusufali Rawjee

Executive Director

Vinod Naik

Independent Non Exe. Director

Manju Agarwal

Independent Non Exe. Director

Taruvai Laxminarayanan Easwar

Chairman (Non-Executive)

HIREN KARSANBHAI PATEL

Independent Director

KAUSHIKBHAI NANDUBHAI PATEL

Independent Director

Savan Godialwala

Company Sec. & Compli. Officer

Rudalf Corriea

Registered Office

Plot No. 170-172 Chandramouli,

Industrial Est.Mohol Bazarpeth,

Maharashtra - 413213

Tel: 91-2189-234456/234246

Website: http://www.glenmarklifesciences.com

Email: [email protected]

Registrar Office

Karvy Selenium Tow-B,

31&32 Financial Dist, Nanakramguda,

Hyderabad-500032

Tel: 91-40-67162222

Website: www.kfintech.com

Email: [email protected]

Summary

Alivus Life Sciences Limited was initially established as Zorg Laboratories Private Limited, on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtr...
Read More

Reports by Glenmark Life Sciences Ltd

Company FAQs

What is the Alivus Life Sciences Ltd share price today?

The Alivus Life Sciences Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹1001.3 today.

What is the Market Cap of Alivus Life Sciences Ltd?

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Alivus Life Sciences Ltd is ₹12278.86 Cr. as of 27 Jun ‘25

What is the PE and PB ratio of Alivus Life Sciences Ltd?

The PE and PB ratios of Alivus Life Sciences Ltd is 25.28 and 4.36 as of 27 Jun ‘25

What is the 52 Week High and Low of Alivus Life Sciences Ltd?

The 52-week high/low is the highest and lowest price at which a Alivus Life Sciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Alivus Life Sciences Ltd is ₹819.05 and ₹1335.1 as of 27 Jun ‘25

What is the CAGR of Alivus Life Sciences Ltd?

Alivus Life Sciences Ltd's CAGR for 5 Years at 5.85%, 3 Years at 30.85%, 1 Year at 18.05%, 6 Month at 1.10%, 3 Month at -0.97% and 1 Month at -9.94%.

What is the shareholding pattern of Alivus Life Sciences Ltd?

The shareholding pattern of Alivus Life Sciences Ltd is as follows:
Promoters - 74.99 %
Institutions - 11.76 %
Public - 13.25 %

Glenmark Life Sciences Ltd Share Price Live

Equities

Futures

Option

Glenmark Life Sciences Ltd KEY RATIOS

Glenmark Life Sciences Ltd Corporate Action

Alivus Life Sciences Ltd NEWS AND UPDATE

Glenmark Set to Enter $421 Million US ADHD Drug Market

Glenmark Life Sciences’ Q2 net profit falls 20% y-o-y

Top stocks for today - 25th October 2024

Glenmark Pharmaceuticals divests stake in Glenmark Life after Nirma Acquisition

Knowledge Center

Demat Account

Trading Account

Alivus Life Sciences Ltd SHAREHOLDING SNAPSHOT

Promoter- 74.99%

Non-Promoter- 11.75%

Glenmark Life Sciences Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Glenmark Life Sciences Ltd Peer Comparison

MORE ABOUT Glenmark Life Sciences Ltd

Management

Register Office

Registrar Office

Company FAQs

QUICKLINKS FOR Glenmark Life Sciences Ltd

Information

Financials

Results

News

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES